Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
VALN Stock Forecast 2025-2026
$9.05
Current Price
$628.01M
Market Cap
Buy 4
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to VALN Price Targets
+98.9%
To High Target of $18.00
+43.6%
To Median Target of $13.00
-34.0%
To Low Target of $5.98
VALN Price Momentum
+3.8%
1 Week Change
-13.8%
1 Month Change
+94.2%
1 Year Change
+107.1%
Year-to-Date Change
-26.1%
From 52W High of $12.25
+150.0%
From 52W Low of $3.62
📊 TOP ANALYST CALLS
Did VALN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Valneva is one of their latest high-conviction picks.
Latest VALN Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, VALN has a bullish consensus with a median price target of $13.00 (ranging from $5.98 to $18.00). The overall analyst rating is Strong Buy (8.4/10). Currently trading at $9.05, the median forecast implies a 43.6% upside. This outlook is supported by 4 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Brandon Folkes at HC Wainwright & Co., projecting a 98.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VALN Analyst Ratings
4
Buy
1
Hold
0
Sell
VALN Price Target Range
Low
$5.98
Average
$13.00
High
$18.00
Current: $9.05
Latest VALN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VALN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 8, 2025 | Guggenheim | Vamil Divan | Buy | Maintains | $13.00 |
| Aug 25, 2025 | HC Wainwright & Co. | Brandon Folkes | Buy | Reiterates | $18.00 |
| Aug 19, 2025 | HC Wainwright & Co. | Brandon Folkes | Buy | Assumes | $18.00 |
| May 8, 2025 | Guggenheim | Vamil Divan | Buy | Maintains | $14.00 |
| Apr 15, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $17.00 |
| Apr 9, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $17.00 |
| Apr 2, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $17.00 |
| Mar 31, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $17.00 |
| Mar 24, 2025 | Guggenheim | Dana Flanders | Buy | Maintains | $15.00 |
| Mar 24, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $17.00 |
| Mar 21, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $17.00 |
| Feb 28, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $17.00 |
| Feb 19, 2025 | HC Wainwright & Co. | Edward White | Buy | Maintains | $17.00 |
| Feb 5, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $18.00 |
| Jan 31, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $18.00 |
| Jan 23, 2025 | HC Wainwright & Co. | Edward White | Buy | Maintains | $18.00 |
| Jan 22, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Oct 11, 2024 | HC Wainwright & Co. | Edward White | Buy | Maintains | $20.00 |
| Sep 25, 2024 | HC Wainwright & Co. | Edward White | Buy | Maintains | $23.00 |
| Sep 3, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $26.00 |
Valneva SE (VALN) Competitors
The following stocks are similar to Valneva based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Valneva SE (VALN) Financial Data
Valneva SE has a market capitalization of $628.01M with a P/E ratio of 72.7x. The company generates $228.14M in trailing twelve-month revenue with a -34.1% profit margin.
Revenue growth is +27.0% quarter-over-quarter, while maintaining an operating margin of -22.0% and return on equity of -38.0%.
Valuation Metrics
Market Cap
$628.01M
Enterprise Value
$1.79B
P/E Ratio
72.7x
PEG Ratio
-16.2x
Price/Sales
4.0x
Growth & Margins
Revenue Growth (YoY)
+27.0%
Gross Margin
+50.1%
Operating Margin
-22.0%
Net Margin
-34.1%
EPS Growth
+47.6%
Financial Health
Cash/Price Ratio
+10.7%
Current Ratio
2.3x
Debt/Equity
105.6x
ROE
-38.0%
ROA
-6.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Valneva SE (VALN) Business Model
About Valneva SE
What They Do
Develops vaccines for infectious diseases.
Business Model
Valneva SE generates revenue by developing and commercializing vaccines that address unmet medical needs, particularly for travel and endemic diseases. Its business model relies on innovation within the biotechnology field and obtaining regulatory approvals to bring its products to market, including its notable VLA2001 COVID-19 vaccine.
Additional Information
The company is headquartered in France and focuses on vector-borne diseases with ongoing projects for Lyme disease and chikungunya. Valneva's collaborations with governments and health organizations highlight its strategic role in enhancing public health, disease management, and pandemic preparedness, contributing to a diversified vaccine portfolio aimed at reducing global health risks.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
700
CEO
Mr. Thomas Lingelbach
Country
France
IPO Year
2021
Website
valneva.comValneva SE (VALN) Latest News & Analysis
Latest News
Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate
11 days ago
Quick Summary
Valneva SE announced positive Phase 1 trial results for VLA1601, its second-generation Zika virus vaccine, showing improved immune response in about 150 participants.
Why It Matters
Positive Phase 1 trial results for Valneva’s Zika vaccine enhance the company's growth potential and could lead to increased investor confidence and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
18 days ago
Quick Summary
Valneva SE will participate in investor conferences in the U.S. and Europe, discussing key value drivers and the Phase 3 trial outcomes for its Lyme disease vaccine, VLA15, partnered with Pfizer.
Why It Matters
Valneva's engagement with institutional investors highlights its focus on transparency and potential growth. The Phase 3 trial outcomes for its Lyme disease vaccine could significantly impact its stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
27 days ago
Quick Summary
Pomerantz LLP is investigating claims for investors in Valneva SE (NASDAQ: VALN). Affected investors can contact Danielle Peyton for more information.
Why It Matters
The investigation into Valneva SE may indicate potential legal issues or financial irregularities, which could impact the company's stock price and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Valneva SE has secured a $500 million debt facility with Pharmakon Advisors, with an initial $215 million to repay existing debt. Up to $285 million may be available for future business development.
Why It Matters
Valneva's $500 million debt facility enhances liquidity, reduces existing debt, and provides funds for future growth, potentially boosting investor confidence and share value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®
1 month ago
Quick Summary
Valneva SE reported positive four-year antibody persistence data for its chikungunya vaccine IXCHIQ®, confirming strong long-lasting immunity across all age groups.
Why It Matters
Positive data on Valneva's chikungunya vaccine shows strong antibody persistence after four years, reinforcing its market potential and competitive edge, which can drive investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
1 month ago
Quick Summary
Pomerantz LLP is investigating claims for Valneva SE (NASDAQ: VALN) investors. Interested parties should contact Danielle Peyton at [email protected] or call 646-581-9980, ext. 7980.
Why It Matters
Valneva SE is under investigation for potential investor claims, signaling possible legal or financial issues that could impact stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About VALN Stock
What is Valneva SE's (VALN) stock forecast for 2026?
Based on our analysis of 6 Wall Street analysts, Valneva SE (VALN) has a median price target of $13.00. The highest price target is $18.00 and the lowest is $5.98.
Is VALN stock a good investment in 2026?
According to current analyst ratings, VALN has 4 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $9.05. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VALN stock?
Wall Street analysts predict VALN stock could reach $13.00 in the next 12 months. This represents a 43.6% increase from the current price of $9.05. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Valneva SE's business model?
Valneva SE generates revenue by developing and commercializing vaccines that address unmet medical needs, particularly for travel and endemic diseases. Its business model relies on innovation within the biotechnology field and obtaining regulatory approvals to bring its products to market, including its notable VLA2001 COVID-19 vaccine.
What is the highest forecasted price for VALN Valneva SE?
The highest price target for VALN is $18.00 from Brandon Folkes at HC Wainwright & Co., which represents a 98.9% increase from the current price of $9.05.
What is the lowest forecasted price for VALN Valneva SE?
The lowest price target for VALN is $5.98 from at , which represents a -34.0% decrease from the current price of $9.05.
What is the overall VALN consensus from analysts for Valneva SE?
The overall analyst consensus for VALN is bullish. Out of 6 Wall Street analysts, 4 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $13.00.
How accurate are VALN stock price projections?
Stock price projections, including those for Valneva SE, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 15, 2025 5:56 AM UTC